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Main conclusions and recommendations
 Two countries in the European Union/European Economic Area (EU/EEA) have reported 
a significant increase in HIV case reports and HIV prevalence among injecting drug 
users (IDUs) during 2011 (Greece and Romania).
 ○ Although the magnitude of the increases in case reports may be partially related to 
enhanced surveillance and active case-finding, evidence indicates a real increase in 
HIV transmission in both countries. 
 ○ There is a temporal association between low levels (or reduction) of provision of 
prevention services in Greece and Romania and these increases. However, any 
causal association is difficult to prove.
 ○ Increased focus on prevention measures, such as needle and syringe programmes 
and opioid substitution treatment, seems essential to prevent new HIV cases among 
IDUs in Greece and Romania. Guidance is given in the ECDC–EMCDDA Guidance 
on the prevention of infectious diseases among people who inject drugs (2011).
 ○ Epidemiological investigation of these outbreaks would facilitate better 
understanding of the current situation to prevent further outbreaks. 
 A few other countries in the EU/EEA report slight increases in HIV among IDUs in 
2010–11. Some countries report increases in injecting risk behaviour or low coverage 
of prevention services among IDUs. These factors combined may indicate a risk for 
increased HIV transmission and future outbreaks. These countries would benefit from 
critically reviewing their national prevention and control programmes. 
 However, about half of the countries in the EU/EEA report a low incidence of HIV cases 
among IDUs, and the overall incidence in the EU/EEA has been declining steadily since 
the early 2000s. These outbreaks show that there is a continuous need to keep public 
health and sufficient preventive services on the agenda in challenging economic times. 
2Background 
Information on disease and risk behaviour 
HIV infection is one of the most serious potential health consequences of injecting drug use, 
leading to chronic infection, AIDS and premature death if untreated [1]. The sharing of needles, 
syringes and other materials for drug injection among several injecting drug users (IDUs) is a 
highly efficient way of transmitting the virus [2]. HIV infection treatment can have great impact 
on public health budgets, especially in countries experiencing economic duress.
Recent estimates for 13 EU Member States and Croatia and Norway indicate large differences 
in the prevalence of injecting drug use [3]. The weighted average estimate is 2.5 per 1 000 
adults aged 15 to 64 years for the Member States providing estimates and Norway. In 
addition, there is a significant population of former IDUs who may have been infected with HIV 
or viral hepatitis. 
EU Member States report HIV prevalence rates among injecting drug users ranging from less 
than 1% to more than 60% (Figure 1) [3, 4]. Of 27 116 newly diagnosed HIV cases reported in 
28 countries in the EU/EEA in 2010, 1 212 were identified as having a current or past history 
of injecting drug use [5]. Since 2004, the number of new HIV diagnoses reported among 
IDUs has declined by 44% in the 26 EU/EEA Member States with consistent HIV reporting 
systems [5]. National trends have been similar during this period, with most countries reporting 
declining numbers of newly reported cases of HIV among IDUs [6, 7]. Despite a decreasing 
trend of HIV cases among IDUs in the EU/EEA, there are still countries where relatively high 
rates of HIV transmission are occurring among IDUs. 
Figure 1: Distribution of HIV prevalence among injecting drug users, by country; Europe, 
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Estonia and Latvia have been the most recent Member States affected by major outbreaks 
among IDUs leading to high prevalence. These outbreaks occurred in the late 1990s and 
the beginning of the new millennium. Since then, they have reported declines, although a 
resurgence of HIV cases was reported in Latvia in 2007, in Lithuania in 2009 and in Bulgaria 
during the past 5 years [3, 5]. Smaller outbreaks without evidence for establishment of high 
prevalence have occurred in Finland in 1997 and on several occasions in Sweden during 
3the last 10 years [8, 9]. In Lithuania, a prison outbreak occurred in 2002 [10]. In most west 
European countries, the HIV epidemic among IDUs is much older and peaked in the mid-1980s 
to early 1990s [11]. 
The potential for blood borne virus outbreaks, establishment of high prevalence and subsequent 
sustained transmission among IDUs is dependent on multiple factors, including the frequency 
of needle sharing, the number of sharing partners and network structures and mixing in the 
injecting drug using population. Additional determinants include the size of the injecting drug 
using population, the types of drugs injected, and awareness of risks and ways and possibilities 
of avoiding them. The perception of the seriousness of the infection may also affect risks. 
Indicators for risk of HIV transmission
The main indicators in use for assessing the epidemiology of HIV among IDUs and the risk of 
increasing transmission are [12]:
 HIV case reports attributed to injecting drug use (case counts or rates per million 
population);
 prevalence of HIV among IDUs, especially among young and new injectors where it is an 
indicator of new infections/incidence;
 data on prevalence of hepatitis C infection can form a valuable indicator of injecting risk 
in populations where HIV has not yet expanded, especially among young or new injectors 
[13, 14];
 other data may give additional information, e.g. changes in drug use patterns can be 
associated with changes in injecting risk. 
Prevention of infections among injecting drug users 
To prevent outbreaks of HIV and other blood borne infections among IDUs, the implementation 
of preventive interventions in a comprehensive manner has been recommended [1, 15]. This 
is independent of the actual incidence of infection. The most robust and recent evidence 
suggests that the largest reduction of HIV and injection risk behaviour can be achieved by 
providing comprehensive prevention services, with high coverage of both needle and syringe 
programmes and opioid substitution treatment in combination [1, 16–18]. 
Event background information
Romania
On 14 November 2011, the national focal point for the EMCDDA and the Ministry of Health 
in Romania notified the detection of a strong increase of newly reported HIV infections among 
IDUs in 2011 by the Romanian HIV surveillance system. While reporting 3 to 5 cases annually 
from 2007 to 2009, HIV infections among IDUs increased to 12 cases in 2010 and to 62 
cases in 2011, as of September. While in 2011, 15% (62/405) of the reported HIV infections 
were found among IDUs, this had been only 3% (12/440) in 2010 and 1% (5/428) in 2009.
Cases reported in 2011 were mostly residents of Bucharest and surrounding area (56/62), 
predominately males (55/62), and younger than 34 years (55/62). Half of these cases were 
diagnosed with HIV infection while being hospitalised for infectious conditions. The remaining 
cases were diagnosed while attending drug substitution treatment centres. In 87% of the 
62 cases, hepatitis C virus (HCV) co-infection was detected. Thirteen newly diagnosed HIV 
infection cases were classified as AIDS cases, suggesting that at least this portion of the cases 
was infected less recently. Of the remaining 49 cases, 29 had a CD4 count at diagnosis higher 
than 500 cells/mm3, suggesting more recent infections.
Other sources, reporting results from the routine HIV testing of IDUs attending drug-related 
treatment services at national level, described an earlier increasing trend of 1% (2/182) in 
2008, 3% (11/329) in 2009 and 4% (12/288) HIV-positive cases among IDUs tested in 2010. 
4HIV prevalence surveys performed in Bucharest in recent years using respondent driven 
sampling techniques showed a constantly low HIV prevalence in IDUs. The latest, part of the 
Behavioural Surveillance Survey 2010 (1), gave an estimate of 1%. Recent data from an NGO 
performing regular HIV testing in 2011 among IDUs in Bucharest, although not based on a 
random sample, described an HIV positivity rate of 5% (17/350). 
As stated by the Romanian Anti-drug Agency, injecting drug use behaviour is concentrated in 
Bucharest where the injecting drug using population size was estimated to be 18 316 in 2010 
(an 11% increase compared to the 16 867 estimated in 2007). An accurate estimate of the 
size of the national IDU population is not available due to the paucity of services/programmes 
outside Bucharest.
Significant changes in drug use patterns were detected through the Behavioural Surveillance 
Survey 2010 in Bucharest, where a higher frequency of injecting behaviour was found and 
where the drug use patterns appear to be changing, with 97% of respondents reporting 
heroin as the main drug of injection in 2009, as compared to 67% in 2010, and with 31% 
of respondents reporting amphetamine-type stimulants as the main drug of injection in 2010. 
There are reports of more frequent injection and needle-sharing associated with stimulant 
use. There are reports that some heroin users have switched to injecting amphetamine-type 
stimulants, mostly synthetic cathinones. These new patterns of use may be associated with a 
higher frequency of injecting. 
While drug use patterns appear to be changing, access to sterile syringes is decreasing. 
Needle and syringe programmes have as yet only been established in the capital city 
Bucharest, and one of the four sites has recently been closed, following the end of external 
funding by the Global Fund for AIDS, TB and Malaria in June 2010. The closure of another 
site is expected in 2012. Decreasing accessibility of needle and syringe programmes is also 
reflected in the results of Behavioural Surveillance Surveys, where the number of respondents 
who report having used a syringe exchange programme decreased from 76% in 2009 to 49% 
in 2010. Furthermore, a reduction in numbers of distributed sterile syringes was reported from 
1.7 million in 2009 to 965 000 in 2010. For 2011, figures available for the year up to October 
show that approximately 700 000 had been distributed. Based on the estimated number of 
IDUs, syringe provision in Bucharest has thus decreased from 97 syringes per IDU in 2009 
to 53 syringes per IDU in 2010. Overall provision of opioid substitution treatment in Romania 
remains very limited, the number of clients in such programmes increased from 424 (2009) to 
601 (2010) [19, 20].
Greece
In July 2011, the Greek member of the EMCDDA Management Board reported that since the 
beginning of 2011, the number of HIV infections reported among IDUs in Greece had risen 
sharply and requested the EMCDDA to issue a warning through the Centre’s early-warning 
system and the network of experts in drug-related infectious diseases. The HIV situation in 
Greece has previously been characterised as a low-level, concentrated epidemic. Between 9 
and 16 cases among IDUs were reported annually during the last 5 years, never representing 
more than 2–3% of all reported cases. During the first 10 months of 2011, cases among IDUs 
increased to 190, representing 25% of the reported cases. A significant increase among cases 
in the ‘unknown’ category was seen. The male to female ratio among IDUs remained constant, 
at around 4 males to 1 female. The age distribution among IDUs has not changed in 2011 [21]. 
A preliminary analysis suggested that immigrant populations may have had a potential role 
in the outbreak [18]. However, it is likely that low service provision has been an important 
contributing factor for increased transmission among migrants and non-migrants, even if 
perhaps combined with a lower access of migrants to these services. In addition, despite a 
relatively high proportion of migrants among the initial cases, the majority of cases among IDUs 
(1) More information is available at: http://www.ana.gov.ro/rapoarte_nationale.php
5Table 1: Injecting drug users (IDUs) in the Greek sentinel surveillance system tested for 
HIV — positive cases and percentage by month in 2011
Month Number of injecting drug users %
Tested for HIV HIV-positive
January 140 4 2.9
February 112 6 5.4
March 143 10 7.0
April 155 11 7.1
May 230 12 5.2
June 162 4 2.5
July 187 14 7.5
August 123 11 8.9
September 329 18 5.5
Total 1 581 90 5.7
Source: OKANA, presented by G. Nikolopoulos.
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in 2011 had Greek nationality and the proportion of cases among non-Greek IDUs decreased 
in 2011. Most HIV cases among IDUs with an immigrant background are from Central Asia or 
the Middle-East and only a few are from Africa.
Greece collects prevalence data on HIV, hepatitis B and C infection among IDUs from three 
separate sentinel surveillance systems in treatment facilities screening clients upon entry. For 
the last decade, HIV prevalence in the sentinel surveillance system for IDUs has remained 
below 2%, a low level compared to other western European Member States. However, in 
2011, all data sources detected a steep increase, reaching 3% to 5% by the end of July 2011 
(Figure 2) [21].
A breakdown of data from one sentinel source (OKANA, Table 1) by month in 2011 suggests 
sustained transmission among IDUs, as positivity rate (prevalence) among those tested is over 
5% in most months during the year.
Figure 2: Distribution of positivity rate (prevalence) of HIV among injecting drug users 
entering treatment, by sentinel surveillance system, Greece, 2002–11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Greek Reitox focal point, reported in [21]. Note: no data are available for 2007. 
6Responses in Greece
Since the detection of the increase in cases at the beginning of 2011, a number of new 
interventions have been introduced. Foremost among these is the rapid expansion of opioid 
substitution treatment services, with the objective of attracting IDUs to care and reducing 
related risks of infectious disease transmission. This effort has been coordinated by the Greek 
organisation against drugs (OKANA), and has significantly reduced mean waiting times for 
entering treatment in the Athens–Piraeus area (from 89 months to 57 months on average) and 
eliminated waiting lists in Thessaloniki. During September 2011, OKANA has launched 17 new 
substitution units, in collaboration with hospitals in Athens and Thessaloniki, whereas by the end 
of the year, 20 new units are planned to be established. Moreover, in order to increase access 
of treatment at the local level, substitution units are to be established in 13 other cities as a part 
of the effort to cover all Greek prefectures.
The Hellenic Centre for Disease Control and Prevention (HCDCP) provides mobile prevention 
services offering information, voluntary testing, referrals and clean needles and syringes in 
Athens. Up to August during 2011, about 60 000 needles and syringes had been distributed, 
an increase from the 33 000 which had been distributed in 2010 by this mobile programme. 
However, the level of activity is still insufficient to meet the demand within the injecting drug 
using population 
Systematic HIV screening of IDUs in treatment programmes has been implemented and an 
awareness campaign directed to IDUs was implemented in the centre of Athens in March 2011. 
A major intervention study is planned by OKANA, HCDCP and Athens University Medical 
School.
Threat assessment for the EU
Assessment of the Romanian outbreak
The low level of provision of opioid substitution treatment and the recent decrease in the 
number of syringes provided through needle and syringe programmes, as well as a recent 
rise in the combined use of opioids and amphetamine-type stimulants resulting in increased 
injecting frequency, could all have contributed to increased HIV transmission. The outbreak of 
HIV among IDUs in Romania is not considered to be an immediate threat to EU countries in 
terms of disease transmission from Romania to other EU countries. However, the circumstances 
of the Romanian outbreak are of relevance to other EU countries in considering prevention and 
surveillance among IDUs. 
Assessment of the Greek outbreak
The outbreak experienced in Greece is comparable to previously described epidemics in 
Europe. Reported infections among IDUs increased from less than 20 cases annually to over 
190 in the first ten months of 2011. Genetic analysis shows close similarity among a subset 
of the viruses sampled from IDUs [22]. This suggests a recent outbreak. Unless efficient and 
comprehensive preventive interventions can be established in Greece, the outbreak may 
result in rapid establishment of long-term high prevalence among this vulnerable group. 
Critical examination of prevention activities and indicators of risk prior to the HIV outbreak in 
Greece identifies several potential weaknesses of the prevention programme which may have 
contributed to the outbreak. Among these, the major factors of vulnerability were the following: 
1) long waiting times for access to opioid substitution treatment (on average 89 months, 
prior to the epidemic); 
2) low (insufficient) volume of injection equipment exchange or provision.
These factors have created favourable conditions for the rapid transmission of HIV in the 
population of users, especially in the Athens area. The surveillance data suggests that cases 
7among the IDUs are mainly Greek nationals and the proportion of individuals with a migrant 
background has decreased in 2011 compared to the previous years.
Assessment of the situation of HIV among IDUs in the EU/EEA
Prevention of infections among IDUs is possible and can be effective if correctly executed. The 
potential threat for the EU Member States consists of the possibility that prevention efforts that 
counteract the spread of HIV among IDUs are not maintained at a level sufficient to prevent 
large scale transmission. New outbreaks are strong indicators of such a lack of effectiveness. 
Without adequate preventive responses, outbreaks among IDUs may lead to high prevalence 
in this population and a heavy future disease burden.
In response to the notified events in Greece and Romania, and following a request from DG 
Sanco, the ECDC and the EMCDDA conducted a joint rapid inquiry to HIV surveillance contact 
points and drug focal points in EU/EEA, candidate and potential candidate countries on 17 
November 2011 to inquire about possible recent increases in HIV infections detected among 
IDUs. Information available from routine surveillance and monitoring of HIV and hepatitis C 
virus (HCV) as well as prevention coverage among IDUs has been combined with results from 
the rapid inquiry (Annex, Table A1).
Six countries reported changes in HIV case reports or prevalence among IDUs compared 
to 2009–10. Seventeen countries reported no changes, four reported fewer cases or lower 
prevalence, and two did not have information available to assess a change. In addition to 
Greece and Romania, countries reporting an increase in the most recent year for which data 
were available (2011 or 2010) were Luxembourg and Lithuania, while regional increases were 
reported by Bulgaria (Sofia only) and Italy (2009, one region out of 21). 
In Bulgaria, HIV case reports for IDUs increased by 9% up to October 2011 in comparison 
with 2010, however data were only available for Sofia. Nationally, case reports for HIV 
among IDUs increased between 2008 and 2009 in Bulgaria. In Luxembourg, drug surveillance 
data showed an increased HIV infection prevalence in current IDUs from 4% in 2009 to 8% in 
2010 (no data for 2011); however, the proportion of all HIV cases for which injection drug use 
is reported as a transmission route declined from 6% in 2010 to 4% in 2011, as of November. 
Increases were reported in three regions in Italy, however, the average national prevalence of 
HIV infection among IDUs continues to decline, and the reported increase in prevalence in one 
region (Veneto) is not confirmed by case reporting data. Lithuania reported an increase in the 
number of HIV cases in 2009 and 2010 (180 and 153 respectively) as compared to 2008 (42 
cases), but also reported enhanced surveillance among IDUs in 2010 and a reporting delay 
which deferred the reporting of 40 of the 2008 cases to 2009.
Bulgaria, Greece and Romania report additional information consistent with increased risk. 
In Bulgaria, increases in injecting risks have been reported. In Romania, the prevalence of 
hepatitis C among IDUs increased between 2005 and 2007 (more recent data are not 
available), suggesting potential earlier increases in injection related risks. The HIV outbreak in 
Greece was also preceded by an increase in HCV prevalence among new IDUs (injecting for 
less than 2 years).
Increases in risk indicators or low coverage of prevention measures have been reported 
from Austria, Croatia, Cyprus, Czech Republic, Hungary, Latvia, Lithuania, Poland, Slovakia 
and Sweden. In some countries, increasing HCV prevalence at national or sub-national level 
(Austria, Cyprus, Italy) might also indicate a higher risk of (localised) HIV outbreaks. Sweden 
experienced an HIV outbreak (2007) while having had long-term low coverage of needle 
and syringe programmes, but continues to have low HIV prevalence among IDUs [9, 23, 24]. 
Indicators of increased injecting risk (increases in mephedrone injecting) are noted in Austria 
and Hungary. An increase in the prevalence of IDUs is reported by the Czech Republic. 
8Analysis of factors contributing to increased risk of HIV transmission in IDUs
Low prevention coverage in some EU countries
Opioid substitution treatment
Opioid substitution treatment is available in all 27 EU Member States, and the number of 
opioid substitution clients in the European Union is estimated at 685 000 (2009), which 
represents a 50% coverage. Provision is, however, considerably variable and regionally 
imbalanced: the share of opioid substitution clients in the 12 countries that joined the EU since 
2004 represents less than 3% of the total in the EU (2). 
The latest opioid substitution coverage rates for 2009/2010 (available for 18 countries, see 
Figure A1 in the Annex) show that Cyprus, Greece, Latvia, Lithuania, Poland and Slovakia are 
characterised by low coverage rates of between 2% and 27%. Problems in access to opioid 
substitution treatment have been documented. As well as the very long waiting times of more 
than 7 years noted earlier in Greece, Hungary and Romania report waiting times that range 
from between one and six months, and Bulgaria and some regions of Poland report waiting 
times of more than one year [3].
For countries where no recent estimate of the number of problem opioid users is available, 
the number of opioid substitution clients per 100 000 adults can be used as a proxy for the 
magnitude of provision. Data show huge variations, ranging from 3 cases per 100 000 adults 
in Romania, 12 in Latvia, 59 in Bulgaria and 111 in Estonia to very high rates of 248 and 329 
opioid substitution clients per 100 000 adults in Spain and France, respectively.
Needle and syringe programmes
Programmes for the exchange or distribution of needles and syringes and other injecting 
equipment exist now in all Member States. However, Sweden and several countries in Central 
and Eastern Europe report lack of availability in some regions [25]. The average number of 
syringes per IDU (3) distributed by specialised programmes in a year ranges from less than 20 
in Cyprus, Greece, Slovakia and Sweden, 39 in Latvia and 69 in Hungary to more than 300 
in Norway. For HIV prevention, an annual distribution of 100 syringes per IDU is considered 
low while an annual distribution of 200 syringes per IDU is reasonably high (Figure A2 in the 
Annex) [15]. Using the estimate for the IDU population size in the capital city of Bucharest, the 
minimum target for annual syringe distribution would be 1.8 million syringes. However, in the 
context of this ongoing outbreak, 3.6 million syringes per year would need to be considered 
for Bucharest only, as compared to the 965 000 syringes that were distributed in the whole of 
Romania in 2010.
Where no current IDU estimates exist, syringe provision can be expressed in terms of the 
general adult population in order to illustrate the differences between countries: rates vary from 
7 syringes per 1 000 adults per year in Poland and 83 in Lithuania to 129 in Bulgaria and 
330 in France.
Economic crises and programme funding 
In past economic downturns, increased HIV incidence and increased injecting drug use have 
been observed [25, 26]. There are reasons to suspect that the current economic turmoil has 
had and will continue to have adverse effects on HIV prevention in Europe [27]. The current 
economic crisis is, for example, expected to have an impact on public health budgets including 
services targeted at vulnerable populations such as IDUs in Europe [28], and it has been 
(2) The 12 Member States that have joined the EU in 2004 and 2007 represent about 20% of the total population 
of the EU.
(3) See Figure HSR-3 in the EMCDDA 2011 Statistical bulletin (http://www.emcdda.europa.eu/stats11/hsrfig3). 
These figures do not include pharmacy sales, which may represent an important source of sterile syringes for 
drug users in several countries.
9observed that government financing for global HIV/AIDS programmes dropped by 10% in 
2010 compared to 2009 [29]. Thus, the EMCDDA noted in its most recent annual report 
that the current economic crisis may increase the risk of localised HIV epidemics among drug 
injectors [3]. Although the current situation in Greece appears to be associated more closely 
with a longer-term lack of service provision than with recent cuts, it is important to ensure 
that the current economic situation does not impact on measures to increase availability of 
prevention services for those in need.  
The combination of an economic crisis, which could affect risk-taking behaviours and 
exacerbate social inequalities, and the phasing out of funding programmes could be 
particularly challenging. In Romania, as noted above, the major grant from the Global Fund to 
Fight AIDS, Tuberculosis and Malaria that focused on providing a wide range of prevention, 
testing and counselling services to IDUs ended in mid-2010 (4). The closure of this grant 
coincides with the five-fold increase of HIV among IDUs in 2011 over 2010, and although 
the extent to which the continuation of services covered in this grant has been provided by 
alternative organisations needs to be further assessed, all evidence suggests that there has 
been an overall decline in prevention programmes.
Available evidence indicates a temporal association between a reduction in, or initially low, 
level of provision of prevention services and an increase in HIV incidence, changes in patterns 
of risk among IDUs in Greece and Romania and this increase. The extent to which these service 
reductions or changing patterns of risk among IDUs have been related to the current economic 
crisis cannot be easily measured, and causal links are impossible to establish. However, based 
on available evidence, the prevalence of injecting drug use may increase during an economic 
crisis and public health budgets may be reduced. These outbreaks show that there is a 
continuous need to keep public health and sufficient preventive services on the agenda, even in 
challenging economic times. 
Changes in drug use patterns — increased stimulant injection in several EU Member States 
in relation to the ‘heroin drought’ in 2010
A recent heroin shortage was documented in some EU countries during 2010–11 [30]. Some 
countries experienced heroin shortages in the first few months of 2011. Some drug users 
reported increasing their use of both alcohol and non-prescribed benzodiazepines when heroin 
was scarce. Furthermore, the illicit use of synthetic opioids (buprenorphine, fentanyl and, to a 
lesser extent, methadone) as replacements for heroin was also reported. The increased use of 
stimulant drugs (crack, amphetamines), sometimes by injection, was also reported, as was the 
replacement of heroin by injectable amphetamine-type stimulants (synthetic cathinones, mostly 
mephedrone). The recent heroin shortage may, therefore, have triggered changes in drug use 
patterns, possibly leading to more frequent injection. However, the overall impact of the short-
lived heroin shortage remains to be fully elaborated.
Changes in surveillance and the role of enhanced testing
Increases in HIV cases in IDUs detected and reported could partially be due to enhanced 
surveillance or increased testing among IDUs. In Greece increased testing was reported in later 
months, after the outbreak was detected. However, Romania has not yet reported enhanced 
testing campaigns in response to the increased cases of HIV. Elsewhere in the EU, most of 
the countries reporting to this rapid risk assessment stated that their HIV surveillance activities 
among IDUs had remained unchanged in 2011 as compared to 2009–10, with only Italy 
reporting decreased testing for HIV among IDUs. 
(4) More information is available at: http://portfolio.theglobalfund.org/en/Grant/Index/ROM-607-G03-H
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Conclusions
Two countries in the EU/EEA have reported a significant increase in HIV case reports and HIV 
prevalence among IDUs during 2011 (Greece and Romania).
 ○ Although the magnitude of the increases in case reports may be partially related to 
enhanced surveillance and active case-finding, evidence indicates a real increase in HIV 
transmission in both countries. 
 ○ There is a temporal association between low levels (or reduction) of provision of prevention 
services in Greece and Romania and these increases. However, any causal association is 
difficult to prove.
 ○ Increased focus on prevention measures, such as needle and syringe programmes and 
opioid substitution treatment, seems essential to prevent new HIV cases among IDUs 
in Greece and Romania. Guidance is given in the ECDC–EMCDDA Guidance on the 
prevention of infectious diseases among people who inject drugs (2011).
 ○ Epidemiological investigation of these outbreaks would facilitate better understanding of 
the current situation to prevent further outbreaks. 
A few other countries in the EU/EEA report slight increases in HIV among IDUs in 2010–11. 
Some countries report increases in injecting risk behaviour or low coverage of prevention 
services among IDUs. These factors combined may indicate a risk for increased HIV 
transmission and future outbreaks. These countries would benefit from critically reviewing their 
national prevention and control programmes. 
However, about half of the countries in the EU/EEA report a low incidence of HIV cases 
among IDUs, and the overall incidence in the EU/EEA has been declining steadily since the 
early 2000s. These outbreaks show that there is a continuous need to keep public health and 
sufficient preventive services on the agenda in challenging economic times. 
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Annex
Table A1. Indicators of HIV and HCV transmission, injecting risk and intervention coverage
  HIV cases 
increase (i)
HIV 
prevalence 
increase
HCV  
prevalence 
increase
Other 
injecting 
risk 
increase
Injection 
drug use 
prevalence 
increase
< 30% of 
problem opioid 
users in opioid 
substitution 
treatment (ii)
< 100 syringes 
per IDU per 
year from 
specialised 
programmes (iii)
Surveillance 
changes
Austria 2010 2010 2010 (14) (a) 52%  
Belgium 2010 2010 2010    
Bulgaria 2009 2010 (1) 2010 (15)  (d)  
Croatia 2010     (b) 89  
Cyprus 2010 2010 (2) 2010 (16) (b) 27%  2010 0  
Czech Republic 2010 2010 2010 (b) 32% 138 
Denmark 2010   2008   
Estonia 2010     164  
Finland 2010 2009 2009 32%  
France 2010      
Germany 2010     55%  
Greece 2011 2011 (3) 2010  (17) (f)  (b) 22%   2010 6   
Hungary 2010 2010 (4) (a,d) (c) 32% 69  
Iceland 2010      
Ireland 2010     (d) 51%  
Italy 2010 2009 (5) 2009 (18)  50%  
Latvia 2010 2010 (6) (7) 2%   2010 39  
Lichtenstein      
Lithuania 2011 (7)   17%   2010  
Luxembourg 2010 2010 (8)   64% 204  
Malta 2010 2010 2010 68% 193  
Netherlands 2010 (9) 2008 60%  
Norway 2010 2010 2010  (b) 57% 309  
Poland 2010 2010 (19) 8%   2010  
Portugal 2010 2010 2009 144  
Romania 2011 2011 (21) 2010 (20)  (e) 53 (h)  
Slovakia 2010 2010 (11) 2010  (d) (c) 12%  2010 19   
Slovenia 2010 2010 2010 (d)  
Spain 2010 2009    
Sweden 2010 2008 (12) 2008 3  
Turkey 2010 (13)    
United Kingdom 
(England)
2010 2010 2010 (d) (g) 56%   2009  
Notes:
(i) HIV case increase taken from 2010 HIV Surveillance data, Source: European Centre for Disease Prevention 
and Control, WHO Regional Office for Europe (2011). In Bulgaria, case reports increased in 2008–09, but 
returned to the 2008 level in 2010. Case increases for Romania and Greece for 2011 were reported from 
national HIV surveillance and drugs focal points. Focal points from most other EU/EEA countries indicated 
no detected increase in new cases among IDUs in 2011 as compared to previous years.
NO ALERT — no evidence for increased cases/prevalence and/or no evidence of low intervention  
coverage/no changes in surveillance.
  ALERT — evidence for increased cases/prevalence and/or low intervention coverage/decreased surveillance.
  Information unknown/not reported to EMCDDA/ECDC.
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(ii) For the purpose of this report a cut-off of 30% coverage was used in order to limit to the alert to the lowest 
range and likely highest HIV risk. Coverage levels below 50–70% of the target population are considered 
sub-optimal. Source: EMCDDA Statistical bulletin 2011, Figure HSR-1 with updates from national focal points 
for Greece, Latvia, Lithuania, Poland, Slovakia and the United Kingdom (England).
(iii) Syringes given out by specialised needle and syringe programmes, not including pharmacy sales. Source: 
EMCDDA Statistical bulletin 2011, Figure HSR-3 [20]. Data up to 2009.
(1) The ratio of HIV positive IDUs for the last 10 months (January to October, 2011) increased by 8.9% in 
comparison with the whole 2010. The available data is for the capital city (Sofia) only.
(2) Increase among young IDUs 2004–09 reported in the EMCDDA Annual report 2011 [3] is not continued in 
2010.
(3) Source: http://www.emcdda.europa.eu/news/2011/update1/greek-report
(4) National trend data until 2009 show no increase, data for 2010 show zero prevalence in 6 regions.
(5) Decline at national level, increase in one out of 21 regions (Veneto), 2004–09.
(6) Increase in self-reported HIV prevalence 2004–09 reported in the EMCDDA Annual report 2011 [3] is not 
continued in 2010.
(7) Varying prevalence in 2010 but no trend data available.
(8) Self-reported data; increase in 2010 reported (see page 6 of this report).
(9) Zero prevalence in Amsterdam and Rotterdam 2010, but small sample sizes and no trends data.
(10) National trend data until 2009 show no increase, data for 2010 show zero prevalence in 6 regions.
(11) Increase in HIV prevalence 2004–09 reported in the EMCDDA Annual report 2011 [3] is not continued in 
2010.
(12) Trend data are available only until 2008, suggest some increase (n.s.).
(13) No trend data available, data 2010 suggest low prevalence.
(14) Increases in Graz and Vienna, 2005–10.
(15) Increase among all IDUs and among young IDUs, Sofia, 2005–10.
(16) Increase among all IDUs 2005–10.
(17) Increase nationally and in Attica, Central Macedonia and Thessaly, 2005–10.
(18) Decrease nationally, increasing trend in three out of the 21 regions (Abruzzo, Umbria, Valle d’Aosta), 
2004–09.
(19) Varying prevalence in 2009, but no trend data available.
(20) Increase 2005–08 in all IDUs, and in male IDUs only in 2008–10.
(21) See page 4 of this report.
(a) Based on the EMCDDA Annual report 2011 [3] both Hungary and Austria reported notable increase of 
mephedrone injecting.
(b) IDU prevalence estimates (important: 2010 data taken into account only for the Czech Republic and 
Greece).
(c) Trend data available but not recent.
(d) Country experienced severe heroin shortage in 2010/2011 and reported on possible increased injecting 
risks for some groups.
(e) Users switched to injecting amphetamine-type stimulants (mostly mephedrone and other synthetic 
cathinones).
(f) Reports of increased injecting of stimulants (home-made) at expert meeting Greece, October 2011.
(g) Injectors of opioids and/or crack-cocaine.
(h) Sub-national estimate, Bucharest area.
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Figure A1: Opioid substitution treatment clients as a percentage of the estimated number 
of problem opioid users, 2010 or most recent year available
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For more details see: Figure HSR-1 in the EMCDDA Statistical bulletin 2011, with 2010 updates for Greece, Latvia, 
Lithuania, Poland, Slovakia and the United Kingdom (http://www.emcdda.europa.eu/stats11/hsrfig1).
Figure A2: Syringes distributed through specialised programmes in 2009 per estimated 
injecting drug user
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For more details see: Figure HSR-3 in the EMCDDA Statistical bulletin 2011  
(http://www.emcdda.europa.eu/stats11/hsrfig3).
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